Outpatient Pearls: Prevention, Screening, and Immunization
Preventive medicine represents the cornerstone of outpatient internal medicine practice. Evidence-based screening and immunization prevent disease progression and reduce morbidity and mortality.
Disease Screening Guidelines
The United States Preventive Services Task Force (USPSTF) provides evidence-based recommendations for population-level screening. Implementing these recommendations improves outcomes while minimizing unnecessary testing.
Cancer Screening
| Cancer Type | Screening Test | Age to Begin | Age to Stop | Screening Interval | Notes |
|---|---|---|---|---|---|
| Colorectal | Colonoscopy or other modalities (FIT, sigmoidoscopy, CT colonography) | 45 | 75 | Every 10 years for colonoscopy | USPSTF lowered starting age from 50 to 45 in 2021; shared decision for 76-85 |
| Breast | Mammography | 50 (shared decision 40-49) | 74 | Every 2 years | Risk stratification affects frequency; discuss benefits/harms |
| Cervical | Pap smear alone or Pap+HPV | 21 (start age) | 65 (stop age) | Every 3 years (Pap); Every 5 years (Pap+HPV) | HPV vaccination reduces screening need; hysterectomy without CIN stops screening |
| Lung | Low-dose CT (LDCT) | 50 | 80 | Annual screening | Requires ≥20 pack-year history; benefit for former smokers within 15 years of quitting |
| Prostate | PSA testing | 55 (shared decision 40-69) | 70 | Depends on baseline | High variability in recommendations; discuss individual risk/preference |
Metabolic and Cardiovascular Screening
| Condition | Screening Test | Population | Frequency | Key Considerations |
|---|---|---|---|---|
| Type 2 Diabetes | Fasting glucose or HbA1c | Age 35-70; BMI ≥25 or overweight | Every 3 years if normal | Screen younger if additional risk factors (family history, prior GDM) |
| Hypertension | Blood pressure measurement | Age 18+ | Annually or at each visit | Home BP monitoring recommended; confirm elevated readings |
| Lipids | Fasting lipid panel | Age 20+ | 4-6 years (varies by risk) | More frequent if known cardiovascular disease or lipid abnormality |
| Abdominal Aortic Aneurysm (AAA) | Abdominal ultrasound, one-time | Men age 65-75 who ever smoked | One-time screening only | Not recommended for never-smokers; not recommended in women |
| Atherosclerotic CVD | Assess 10-year risk using calculator | Age 40-75 | Periodically | Framingham or pooled cohort equations inform statin initiation |
Infectious Disease Screening
| Infection | Screening Test | Population | Frequency | Management if Positive |
|---|---|---|---|---|
| Hepatitis C Antibody | Anti-HCV antibody, confirmatory HCV RNA | All adults age 18-79 | One-time minimum | Refer for treatment if RNA positive; all HCV curable with DAA therapy |
| HIV | 4th generation antigen/antibody test | All age 15-65; higher risk more frequently | At least once in lifetime; annual for higher-risk populations | Urgent antiretroviral therapy; long-term suppression possible |
| Syphilis | RPR/VDRL with FTA-ABS or TP-PA confirmatory | High-risk populations; all pregnant women | Based on risk; annual for MSM | Early treatment prevents progression; latent syphilis still infectious |
| Tuberculosis | TST (tuberculin skin test) or IGRA (interferon-gamma release assay) | Contacts of TB cases; recent immigrants from endemic areas | As indicated | Treat latent TB to prevent active disease |
Osteoporosis and Bone Health
| Screening | Population | Method | Frequency | Treatment Threshold |
|---|---|---|---|---|
| Osteoporosis | Women ≥65; men ≥70; postmenopausal women <65 with risk factors | DEXA scan (dual-energy X-ray absorptiometry) | Every 2 years if T-score -1.0 to -2.5; annual if T-score <-2.5 | T-score ≤-2.5 or T-score -1 to -2.5 with risk factors |
Mental Health and Substance Abuse Screening
| Condition | Screening Tool | Population | Positive Result Management |
|---|---|---|---|
| Depression | PHQ-9 (Patient Health Questionnaire-9) or shorter PHQ-2 | All adults; more frequent in chronic disease | Refer for counseling; consider antidepressant therapy |
| Alcohol Misuse | AUDIT (Alcohol Use Disorders Identification Test) or AUDIT-C (3-item version) | All adults | Counsel on reduction; refer to addiction specialist if SUD diagnosed |
| Drug Use | NIDA Quick Screen or OARRS (prescription drug monitoring program) | All adults; mandatory in opioid-prescribing practices | Urine drug screening; refer to addiction services; avoid opioid prescribing |
| Intimate Partner Violence | HARK or other validated screening | All women; men if available resources | Safety assessment; referral to social work and community resources |
Immunization Schedules and Recommendations
Vaccination represents one of medicine's greatest public health achievements. Adult immunization schedules change regularly based on emerging evidence and epidemiology.
Core Adult Immunizations
| Vaccine | Schedule | Target Population | Booster/Revaccination | Special Populations |
|---|---|---|---|---|
| Influenza (Flu) | Annual single dose (most adults) | All adults ≥6 months; especially ≥65 or chronic disease | Annual fall/early winter | High-dose or adjuvanted for ≥65 |
| Tdap | One-time dose if not previously given | All adults, especially if >10 years since last Td | Td booster q10 years | Pregnant women get Tdap; non-pregnant can get Td |
| Pneumococcal - PCV20 | Single dose given to all ≥65 or high-risk | All ≥65; chronic lung/heart disease; diabetes; smoking; CSF leak | No revaccination if PCV20 given | Can follow with PPSV23 per guidelines if prior PPSV23 given |
| Pneumococcal - PCV15+PPSV23 | PCV15 now, PPSV23 in 1 year (if not prior) | Age 65+; chronic disease; smoking | ≥1 year between PCV15 and PPSV23 | Algorithm more complex for prior PPSV23 recipients |
| Shingles (Shingrix) | Two doses, 2-6 months apart | All ≥50; immunocompetent individuals | No booster needed | Prior Zostavax recipients should get Shingrix |
| Hepatitis B | 3-dose series (standard) or 2-dose (high-dose Heplisav-B) | All non-immunized adults; age 19-59 routinely; ≥60 at risk or shared decision | Consider anti-HBs testing to confirm response | Immunocompromised may need higher doses or additional doses |
| HPV (Gardasil-9) | 2 or 3-dose series depending on age | Through age 26 (routinely); shared decision-making ages 27-45 | None standard; may revaccinate in special situations | Dosing: 2 doses if started at age 12-14; 3 doses if started ≥15 or immunocompromised |
| COVID-19 | Primary series then boosters | All age 6 months+ | Boosters per current epidemiology; frequency variable | Immunocompromised require additional primary doses + boosters |
| Varicella | 2 doses, 4+ weeks apart | Non-immune adults; no prior vaccination or serology negative | No routine booster | Contraindicated in pregnancy; wait 4 weeks before pregnancy |
| Measles, Mumps, Rubella (MMR) | 1-2 doses depending on birth year; non-immune adults | All without immunity; born 1957+ benefit from 2 doses | No routine booster | Contraindicated in pregnancy; check immunity status first |
High-Risk Population Immunizations
| Vaccine | Indication | Schedule | Special Considerations |
|---|---|---|---|
| Hepatitis A | Chronic liver disease, HAV non-immune, MSM, IVDU, travel | 2 doses, 6-12 months apart | Some combination vaccines available (Hep A + B) |
| Meningococcal (MenACWY) | Age 16-23 (1 or 2 doses depending on product); college students; asplenic; terminal complement deficiency | Based on vaccine type and risk | Serogroup B requires separate vaccine |
| Meningococcal B (Bexsero/Menhibrix) | Asplenic patients, complement deficiency, MenB outbreaks | 2 doses, 1 month apart | Separate from MenACWY; time intervals matter |
| Pneumococcal (PPSV23) | Chronic disease, smoking, age 65+, asplenic, immunocompromised | 1 dose; may repeat ≥1 year later if immunocompromised | Now often follows PCV20 or PCV15 |
| Tuberculosis (BCG) | Only in non-immunized healthcare workers with frequent TB exposure | Single dose | Not routinely given in US; rare use |
| Yellow Fever | Travel to endemic areas; occupational exposure | Single dose; booster q10 years for ongoing risk | Consult travel medicine for destination-specific guidance |
| Rabies (Pre-exposure) | Veterinarians, wildlife handlers, lab workers | 3-dose series over 3-4 weeks | Post-exposure prophylaxis very different; may be lifesaving |
| Japanese Encephalitis | Travel to endemic areas; extended stay in high-risk season | 2-dose series | Consider based on specific travel itinerary |
Immunization Documentation
Always document vaccine name, date, lot number, injection site, and manufacturer. Verify immunity status with serology when indicated. Maintain accurate records and provide patients with documentation for their records.
Screening for Common Conditions
Cardiovascular Risk Assessment
For primary prevention, calculate 10-year atherosclerotic cardiovascular disease (ASCVD) risk using validated tools. Discuss statin therapy, lifestyle modification, and blood pressure targets.
10-Year ASCVD Risk Calculator
Use pooled cohort equation or Framingham risk score: - Low risk (<5%): Lifestyle modification, no statin - Borderline (5-7.5%): Consider statin based on shared decision-making - Intermediate (7.5-20%): Moderate- to high-intensity statin - High risk (>20%): High-intensity statin + aggressive BP/lifestyle management
Cognitive Impairment Screening
Cognitive decline in older adults warrants formal assessment. Brief Cognitive Impairment Screen (BCIS) or Montreal Cognitive Assessment (MoCA) identify mild cognitive impairment requiring further evaluation.
Vision and Hearing Assessment
Age-appropriate vision and hearing screening identify modifiable causes of functional limitation. Refer for audiology and ophthalmology as indicated. Hearing aids and glasses significantly improve quality of life and fall risk.
Last update:
April 12, 2026